Bono-backed biotech bags $45-million Series B

In Dublin, a biotech firm that counts U2 rockers Bono and The Edge among its early backers has raised an additional $45 million.

Nuritas aims to launch its first two products—a peptide for skin health first identified in peas and a muscle health peptide found in fava beans—in 2022.

The Series B funding brings its total fund raise to $75 million. The company plans to eventually expand into food ingredients using its Nπϕ™ peptide finder platform, and has partnerships with food majors such as Nestle and Mars.

“It has been a landmark year, resulting in the expansion of our peptide portfolio, growing the commercial team and developing key global partnerships,” says Dr. Nora Khaldi, founder and CEO of Nuritas. “Our new investors bring a wealth of invaluable expertise, and this latest round will help to build our US headquarters, continue to expand our team, scale our platform to discover more life-changing ingredients and accelerate our route to market.”

The latest funding was led by Cleveland Avenue, LLC, and included Grosvenor’s Wheatsheaf Group, the European Circular Bioeconomy Fund, Singapore-based Vertex Holdings, Nutresa Ventures/ Veronorte and CJ.

More on the story.